Comparison of the Treatment Efficiency of Bone Marrow‐Derived Mesenchymal Stem Cell Transplantation via Tail and Portal Veins in CCl4‐Induced Mouse Liver Fibrosis

• DOI: 10.1155/2016/5720413
• Publication Date: 2015-12-29T21:17:07Z
• Authors: Nhung Hai Truong; Nam Hai Nguyen; Trinh Van Le; Ngoc Bich Vu; Nghia Huynh; Thanh Van Nguyen; Huy Minh Le; Ngoc Kim Phan; Phuc Van Pham
• Keywords: Cell biology; Mechanisms and Treatment of Liver Fibrosis; Cancer research; 03 medical and health sciences; Health Sciences; Genetics; Pathology; Bone marrow; Internal medicine; Biology; Liver Transplantation and Graft Survival Analysis; Mesenchymal stem cell; Transplantation; 0303 health sciences; Stem cell; Hepatology; Mesenchymal Stem Cells; RC31-1245; Fibrosis; 3. Good health; Cirrhosis; Multipotent Mesenchymal Stem Cells; FOS: Biological sciences; Medicine; Surgery; Research Article

Because of self-renewal, strong proliferation in vitro, abundant sources for isolation, and a high differentiation capacity, mesenchymal stem cells are suggested to be potentially therapeutic liver fibrosis/cirrhosis. In this study, we evaluated the treatment effects mouse bone marrow-derived (BM-MSCs) on cirrhosis induced by carbon tetrachloride. Portal tail vein transplantations were examined evaluate different injection routes model at 21 days after transplantation. BM-MSCs transplantation reduced aspartate aminotransferase/alanine aminotransferase levels injection. Furthermore, positive changes serum bilirubin albumin downregulated expression integrins (600- 7000-fold), transforming growth factor, procollagen-α1 compared with control group. Interestingly, both ameliorated inflammation scores. All mice groups had scores no cirrhosis. conclusion, via or portal veins ameliorates mice. Notably, there differences between administrations. consideration safety, suggest transfusion peripheral as potential method fibrosis treatment.